Изучение механизмов резистентности клеток меланомы человека к противоопухолевой терапии
Диссертация
Сообщения в ряде литературных источников свидетельствуют о том, что в клетках меланомы помимо АВСВ1 (MDR1), АВСС1 (MRP1) и АБСА (LRP) обнаружены транспортеры ABCG2 и АВСВ5. Известно, что активность ABCG2 не снижается в присутствии VP. Сведения о чувствительности АВСВ5 к VP пока отсутствуют, но, учитывая его высокую структурную гомологию с транспортером АВСВ1, способность использовать Rho-123… Читать ещё >
Список литературы
- Dupin Е, Le Douarin NM Development of melanocyte precursors from the vertebrate neural crest//Oncogene. 2003. — Vol. 22(20). — P. 3016−3023.
- Кошевенко Ю.Н. Кожа человека. M.: Медицина. — 2006. — Т. 1.- 357с.
- Клинические рекомендации//Под ред. Чиссова В. И., Дарьяловой C.JI. М.: ГЭОТАР-Медиа, 2006. — 720 с.
- Chin L., Garraway L.A. and Fisher D.E. Malignant melanoma: genetics and therapeutics in the genomic era//Genes Dev. 2006. Vol. 20(16). — P. 2149−2182.
- Онкология/под ред. Чиссова В. И., Дарьяловой C.JI. М.: ГЭОТАР-Медиа, 2007. — 560 с.
- Клиническая диагностика меланомы кожи /Avril M.F., Cascinelli N. et al.- под ред. Л. В. Демидова. 2007. — 360 с.
- Руководство по химиотерапии опухолевых заболеваний/Егоров Г. Н- под ред. Н. И. Переводчиковой. М.: Практическая медицина, 2005. — с. 177 182.
- Balch С.М. Cutaneous melanoma: prognosis and treatment results worldwide//Semin. Surg. Oncol. 1992. — Vol. 8. — P. 400−414.
- Северин С.Е., Москалева Е. Ю. Новые методы клеточной противоопухолевой терапии//Вестник НИИ молекулярной медицины. М.: «Издательский дом «Русский врач», 2007. — Выпуск 7. — С. 51−76.
- Serrone L, Hersey P. The chemoresistance of human malignant melanoma: an update//Melanoma Res. 1999. — Vol. 9(1). — P. 51−58.
- Helmbach H, Sinha P, Schadendorf D. Human melanoma: drug resistance/ZRecent Results Cancer Res. 2003. — Vol. 161. — P. 93−110.
- Жестянников В.Д. Репарация ДНК и ее биологическое значение.- Л.: Наука.-1979. С. 285.
- Москалева Е.Ю., Илюшина Н. А. Повреждения ДНК при действии ионизирующих излучений и их репарация.- М.: Итоги науки и техники. ВИНИТИ. Сер. Радиационная биология. 1990. — Т. 9. — С. 3−113.
- Белушкина Н.Н., Белецкий И. П., Молекулярно-медицинские аспекты клеточной гибели. В книге «Введение в молекулярную медицину"//под ред. М. А. Пальцева, М.: Медицина. 2004. — с. 414−444.
- Барышников А.Ю., Шишкин Ю. В. Иммунологические проблемы апоптоза//УРСС. Москва. — 2002. — 320 с.
- Москалева Е.Ю., Северин С. Е. Возможные механизмы адаптации клетки к повреждениям, индуцирующим программируемую гибель. Связь с патологией./ЛТатологическая физиология. 2006. — № 2. — С. 5−12.
- Ashkenasi A., Dixi V.M. Death receptors: signalling and modulation//Science. 1998. -Vol. 281.-P. 1305−1308.
- Beyaeit R. VLG, Heyninck K, Vandenabeele P. Signaling to gene activation and cell death by tumor necrosis factor receptors and Fas//Int. Rev. Cyt. 2002. -Vol. 214.-P. 225−272.
- Boldin M.P., Goncharov T.M., Goltsev Y.V., Wailad D. Involvement of MACH, a novel MORTl/FADD-imeracting protease, in Fas/APO-1- and TNF receptor-induced cell death//Cell. 1996. — Vol. 85. — P. 803−815.
- Strasser A, Harris A.W., Huang D.C., Krammer P.H., Cory S. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis//EMBO J. — 1995. -Vol. 14.-P. 6136−6147.
- Karin M., Lin A. NF-/cB at the crossroads of life and death//Nature immunol. 2002. — Vol. 3. — P. 221−227.
- Ashkenazi A., Pai R.C., Fong S. et al/ Safety and antitumor activity of recombinant soluble Apo-2 ligand//J. Clin. Invest. 1999. — Vol. 104. — P. 155 162.
- Scaffidi C., Fulda S., Srivivisan et al. Two CD95(APO-l/Fas) signalling pathways//EMBО J. 1998. — Vol. 17. — P. 1675−1687.
- Fulda S., Meyer E., Friesen C. et al. Cell type specific involvment of death receptors and mitochondrial pathways in drug-induced apoptosis//Oncogene. — 2001. Vol. 20. -P. 1063−1075.
- Memon S. A, Moreno M. B, Petrak D, Zacharchuk C.M. Bcl-2 blocks glucocorticoid- but not Fas- or activation-induced apoptosis in a T-cell hybridoma//Jmmunol. 1995. — Vol. 155. — P. 4644−4652.
- Lacronique V, Mignon A, Fabre M, Viollet B, Rouquet N, Molina T, Porteu A, Henrion A, Bouscary D, Varlet P, Joulin V, Kahn A: Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice//Nat. Med. 1996. -Vol. 2.-P. 79−86.
- Friesen C, Fulda S, Debatin K.M. Cytotoxic drugs and the CD95 pathway//Leukemia. 1999. — Vol. 13(11). — P. 1854−1858. Review.
- Fulda S, Friesen C, Debatin K.M. Molecular determinants of apoptosis induced by cytotoxic drugs//Klin. Padiatr. 1998. — Vol. 210(4). — P. 148−152.
- Fulda S, Los M, Friesen C, Debatin K.M. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system//Int. J. Cancer. 1998. -Vol. 76(1).-P. 105−114.
- Los M, Hen-1, Friesen C, Fulda S, Schulze-Osthoff K, Debatin K.M. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases)//Blood. 1997. — Vol. 90(8). — P. 3118−3129.
- Friesen C, Fulda S, Debatin K.M. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells/ZLeukemia. 1997. — Vol. 11(11). — P. 18 331 841.
- Tolomeo M., Dusonchet L., Meli M., Grimaudo S., D’Alessandro N., Papoff G., Ruberti G., Rausa L. The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis//Cell Death Differ. 1998. — Vol. 5(9). — P. 735−742.
- Tomas W.D., Hersey P. CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95)//Int. J. Cancer. 1998. — Vol. 75(3). — P. 384−390.
- Rivoltini L. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand- induced apoptosis and use Fas/FasL-independent mechanisms for tumor killing//J. Immunol. 1998. — Vol. 161(3). — P. -1220−1230.
- Shukuwa Т., Katayama I., Takehiko K. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas//Mod. Pathol. 2002. — Vol. 15(4). — P. 387−396.
- Rivoltini L., Carraba M., Huber V., Castelly C., Novellino L., Dalerba P., Mortarini R., Arancia A., Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction//Immunol. Rewiews. 2002. — Vol. 188. — P. 97−113.
- Classen C.F., Fulda C., Debatin K.M. Decreased sensitivity of drug-resistant cells towards T cell cytotoxicity//Leukemia. 1999. — Vol. 13(3). — P. 410−418.
- Owen-Schaub L, Chan H, Cusack JC, Roth J, Hill LL Fas and Fas ligand interactions in malignant disease/Ant. J. Oncol. 2000. — Vol. 17(1). — P. 5−12.
- Micheau O., Solary E., Hammann A., Dimanche-Boitrel M.T. Fas-ligand independent, FADD-mediated activation of the Fas death pathway by anticancer drugs//J. Biol. Chem. 1999. — Vol. 274. — P. 7987−7992.
- Landovski Т.Н., Qu N., Buyksal I. et al. Mutations in Fas antigen in patients with multiple mieloma//Blood. 1997. — Vol. 90. — P. 4266−4270.
- Tschopp J., Irmler M., Thome M. Inhibition of Fas death signals by FLIPs//Curr. Opin. Immunol. 1998. — Vol. 10. — P. 552−558.
- Xiao C., Yang B. F, Asadi N et al. TRAIL-induced death inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells//J. Biol. Chem. 2002. — Vol. 277. — P. 25 020−25 025.
- Adams J. M, Cory S. Apoptosomes: Engines for caspase activation//Curr. Opin. Cell Biol. 2002. — Vol. 14. — P. 715−720.
- Zou H, Henzel WJ, Liu X, Lulschg A, Wang X: Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3//Cell. 1997. — Vol. 90. — P. 405−413.
- Jiang X, Wang X: Cytochrome promotes caspase-9 activation by inducing nucleotide binding to Apaf-1//J. Biol. Chem. 2000. Vol. 275. — P. 3 119 931 203.
- Stennieke H. R, Devcraux Q. L, Humke E. et al. Caspase-9 can be activated without proteolytic processing//J. Biol. Chem. 1999. — Vol. 274. — P. 8359−8362.
- Slee E. A, Harte M. T, Kluclc R. et al. Ordering the cytochrome С initiated caspase cascade: Hierarchical activation of caspases-2,-3,-6,-7,-8 and-10 in a caspase-9 — dependent manner//! Cell Biol. — 1999. — Vol. 144. — P. 281−292.
- Susin S. A, Lorenzo H. K, Zamzami N. et al. Molecular characterization of mitochondria apoptosis inducing factor//Nature. 1999. — Vol. 397. — P. 441−446.
- Susin S. A, Daugas E, Ravagnan L. et al. Two distinct pathways leading to nuclear apoptosis//J. Exp. Med. 2000. — Vol. 192. — P. 571−580.
- Li L. Y, Luo X, Wang X: Endonuclease G is an apoptotic DNase when released from mitochondria.//Nature. 2001. — Vol.412. — P. 95−99.
- Van Loo G, Schotte P, van Gurp M. et al. Endonuclease G: A mitochondria protein released in apoptosis and involved in caspase-independent DNA degradation//Cell Death. Differ. 2001. — Vol. 8. — P. 1136−1142.
- Widlak P, Li L. Y, Wang X, Garrard W. T Action of recombinant human apoptotic endonuclease G on naked DNA and chromatin substrates: Cooperation with exonuclease and DNase I//J. Biol. Chem. 2001. — Vol. 276. — P. 4 840 448 409.
- Verhagen A.M., Ekert P.G., Pakusch M. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing TAP proteins//Cell. 2000. — Vol. 102. — P. 43−53.
- Du C., Fang M., Li Y. et al. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition//Cell. 2000. — Vol. 102. — P. 33−42.
- Huang H, Joazeiro C. A, Bonfoco E, et al. The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases-3 and 7//J. Biol. Chem. -2000. Vol. 275.-P. 26 661−26 664.
- Gray C. W, Ward R. V, Karran E. et al. Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response//Eur. J. Biochem. 2000. — Vol. 267. — P. 5699−5710.
- Martins L. M, Laccarino I, Tenev I. et al. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif//J. Biol. Chem. 2002. — Vol. 277. — P. 439−444.
- Faccio L, Fusco C, Chen A. et al. Characterization of a novel human serine protease that has extensive homology to bacterial heat-shock endoprotease HtrA and is regulated by kidney ischemia//J. Biol. Chem. 2000. — Vol. 275. — P. 2581−2588.
- Dohi Т., Beltrami E., Wall N.R., et al. Mitochondrial surviving inhibits apoptosis and promotes tumorigenesis//J. Cli. Invest. 2004. — Vol. 114(8). — P. 1117−1127.
- Narita M, Shimizu S, Ito T. et al. Bax interacts with the permeability transition pore to induce permeability transition and cytochrome с release in isolated mitochondria//Proc. Natl. Acad. Sci. USA. 1998. — Vol.'95. — P. 14 681−14 686.
- Marzo I, Brenner C, Zamzanii N. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis//Science. 1998. — Vol. 281. -P. 2027−2031.
- Schendel S. L, Azimov R, Pawlowski K. Ion channel activity of the only Bcl-2 family member, BID//J. Biol. Chem. 1999. — Vol. 274. — P. 21 932−21 936.
- Kudla G, Montessuit S, Eskes R. et al. The destabilization of lipid membranes induced by the C-terminal fragment of caspase-8-cleaved bid is inhibited by the N-terminal fragment/Л. Biol. Chem. 2000. — Vol. 275. — P. 22 713−22 718.
- Woo R.A., McLure K. G, Lees Miller S. P et al. DNA-dependent kinase acts upstreem of p53 in response to DNA damage//Nature. 1998. — Vol. 394. — P. 700−704.
- Morrison С., Sonoda E., Takano N et al. The controlling role of ATM in homologous recombinational repair of DNA damage//EMBO J. 2000. — Vol. 19. -P. 463−471.
- Canman Ch.E., Kastan M.B. Role p53 in apoptosis//Advances in pharmacol.- 1997. Vol. 41. -P. 429−460.
- Oda E, Ohki R, Murasawa H. et al. Noxa, a ВНЗ-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis/VScience. 2000. -Vol. 288.-P. 1053−1058.
- Nakano K, Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53//Mol. Cell. 2001. — Vol. 7. — P. 683−694.
- Cox L.S., Hupp Т., Midgley C.A., Lane D.P. A direct effect of activated human p53 on nuclear DNA replication//EMBO J. 1995. — Vol. 14. — P. 20 992 105.
- Wang X.W., Forrester K., Yeh H. et al. Hepatitis В virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERC3//Proc. Natl. Acad. Sci. USA. 1994. — Vol. 91. — P. 2230−2234.
- Wang X.W., Vermeulen W., Coursen J.D. et al. The X PB and X PD helicases are components of the p53-mediated apoptosis pathway//Genet. Dev. -1996.-Vol. 10.-P. 1219−1232.
- Blagosklonny M. V, El-Dairy W.S., Acute overexpression in wt p53 facilitates anticancer drug-inducer death of cancer and normal cells/Tint. J. Cancer.- 1998. Vol. 75. — P. 933−940.
- Komarov P. G, Komarova E.A., Kondratov R.V. et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy//Science. 1999. -Vol. 285.-P. 1733−1737.
- Zhivotovsky B, Orrenius S. Defects in the apoptotic machinery of cancer cells: role in drug resistance//Semin. Cancer Biol. — 2003. Vol. 13(2). — P. 125 134.
- Marimoto R.I. Cells in stress: transcriptional activation of heat shock genes//Science. 1993. — Vol. 259. — P. 1409−14 100.
- Frydman J. Folding of newly translated proteins in vivo: the role of molecular chaperones//Ann. Rev. Biochem. 2001. — Vol. 70. — P. 603−647.
- Solary E., Droin N., Sordet O. et al. Cell death pathways as targets for anticancer drugs/Яп «Anticancer Drug Development» Academic Press. 2002. -P. 55−76.
- Samali A., Cai J., Zhivotovsky В., et al. Presence of a proapoptotic complex of procaspase-3, Hsp60 and Hsp 10 in the mitochondrial fraction of Jurlcat cells//EMBO J. 1999. — Vol. 18. — P. 2040−2048.
- Xanthoudakis S., Roy S., Rasper D. et al. Hsp60 accelerates the maturation of pro-caspase-3 by upstream activator proteases during apoptosis//EMBO J. -1999. Vol. 18. — P. 2049−2056.
- Gabai V.L., Meriin A., Mosser A.B., et al. Hsp70 prevents activation of stress kinases. A novel pathway of cellular thermotolerance//J. Biol. Chem. -1997.-Vol. 272.-P. 18 033−18 037.
- Jaattela M. Heat shock proteins as cellular lifeguards//Ann. Med.-- 1999. -Vol. 31.-P. 261−271.
- Jaattela M., Wissing D., Kokholm K., et al. Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases//EMBO J. 1998. — Vol. 17. -P. 6124−6134.
- Mehlen P., Schulze-Osthoff K., Arrigo A.P. Smoll stress proteins as novel regulators of apoptosis. Heat shock protein 27 blocks Fas/APO-1- and staurosporine-induced cell death//! Biol. Chem. 1996. — Vol. 271. — P. 16 510 -16 514.
- Garido C., Ottavi P., Fromentin A. et al. HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs//Cancer Res.1997.-Vol. 57.-P. 2661−2667.
- Garido C., Fromentin A., Bonnote В., et al. Heat shock protein 27 enhances the tumorigenicity of immunogenic rat colon carcinoma cell clones//Cancer Res.1998. Vol. 58. — P. 5495−5499.
- Garido C., Bruey J., Fromentin A. et al. HSP27 inhibits cytochrome с -dependent activation of procaspase-9//FASEB J. 1999. — Vol. 13. — P. 20 612 070.
- Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy/Л. Leukoc. Biol. 2007. — Vol. 81(1). — P. 15−27.
- Parcellier A, Gurbuxani S, Schmitt E, Solary E, Garrido C. Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways/ZBiochem. Biophys. Res. Commun. 2003. — Vol. 304(3). — P. 505−512.
- Grossman D, Altieri DC. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets//Cancer Metastasis Rev. 2001. -Vol. 20.-P. 3−11.
- Bradbury P.A., Middleton M.R. DNA repair pathways in drug resistance in melanoma//Anticancer Drugs. 2004. — Vol. 15(5). — P. 421- 426.
- Zhang XY, Zhang XD, Borrow JM, Nguyen T, Hersey P Translational control of tumor necrosis factor-related apoptosis-inducing ligand death receptor expression in melanoma cells//J. Biol. Chem. 2004. — Vol. 279(11). — P. 1 060 610 614.
- Piras F, Perra MT, Murtas D, Minerba L, Floris C, Maxia C, Demurtas P, Ugalde J, Ribatti D, Sirigu P. Combinations of apoptosis and cell-cycle control biomarkers predict the outcome of human melanoma//Oncol. Rep. 2008. — Vol. 20(2).-P. 271−277.
- Liu T, Biddle D, Hanks AN, Brouha B, Yan H, Lee RM, Leachman SA, Grossman D. Activation of dual apoptotic pathways in human melanocytes and protection by surviving//J. Invest. Dermatol. 2006. — Vol. 126(10). — P. 22 472 256.
- Lazaris AC, Theodoropoulos GE, Aroni K, Saetta A, Davaris PS. Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma.//Virchows Arch. 1995. -Vol. 426(5).-P. 461−467.
- Ricaniadis N, Kataki A, Agnantis N, Androulakis G, Karakousis CP. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma//Eur. J. Surg. Oncol. 2001. — Vol. 27(1), — P. 88−93.
- Kalogeraki A, Garbagnati F, Darivianaki K, Delides GS, Santinami M, Stathopoulos EN, Zoras O. HSP-70, C-myc and HLA-DR expression in patients with cutaneous malignant melanoma metastatic in lymph nodes//Anticancer Res. 2006. -Vol. 26. — P.3551−3554.
- Choi Ch.-H. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal//Cancer Cell International. -2005.-Vol. 5.-P. 30−43.
- Dean M. The genetics of ATP-binding cassette transporters//Methods Enzymol. 2005. — Vol. 400. — P. 409−429.
- Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily//J. Lipid Res. 2001. — Vol. 42(7). — P. 1007−1017.
- Gottesman M.M., Fojo Т., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters//Nat. Rev. Cancer. 2002. — Vol. 2. — P.48−58.
- Goodell M.A., Rosenzweig M., Kim H., et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species//Nat. Med. 1997. — Vol. 3. — P. 1337−1345.
- Reya Т., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells//Nature. 2001. — Vol. 414. — P.105−111.
- Sell S. Stem cell origin of cancer and differentiation therapy//Crit. Rev. Oncol. Hematol. 2004. — Vol.51. — P. 1−28.
- Bjerkvig R., Tysnes B.B., Aboody K.S., et al. The origin of the cancer stem cell: current controversies and new insights//Nat. Rev. Cancer. 2005. — Vol. 5. -P.899−904.
- Dalerba P., Cho R.W., Clarke M.F. Cancer stem cells: models and concepts//Annu. Rev. Med. 2007. — Vol. 58. — P.267−284.
- Zhou S., Schuetz J.D., Bunting K.D. et al. The ABC transporter Bcrpl/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype//Nat. Med. 2001. — Vol. 7. — P. 1028−1034.
- Hirschmann-Jax C., Foster A.E., Wulf G.G. et al. A distinct «side population» of cells with high drug efflux capacity in human tumor cells//Proc. Natl. Acad. Sci. USA. 2004. — Vol. 101. — P. 14 228−14 233.
- Wang J., Guo L.P., Chen L.Z. et al. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line//Cancer Research.- 2007. Vol. 67. — P.3716−3724.
- Zen Y., Fujii Т., Yoshikawa S. et al. Histological and culture studies with respect to ABCG2 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma//Am. J. Pathol. 2007.- Vol. 170. — P.1750−1762.
- Raghu G., Park S.W., Roninson I.B., Mechetner E.B. Monoclonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes//Exp. Hematol. 1996. — Vol. 24. — P. 1258−1264.
- Drach J., Gsur A., Hamilton G. et al. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and mterferon-7 in normal human T lymphocytes//Blood. 1996. — Vol. 88. — P.1747−1754.
- Dean M., Fojo Т., Bates S. Tumour stem cells and drug resistance//Nat. Rev. Cancer. 2005. — Vol. 5. — P.275−284.
- Berger W, Hauptmann E, Elbling L, Vetterlein M, Kokoschka EM, Micksche M. Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells/Ant. J. Cancer. 1997. — Vol. 71(1). -P. 108−115.
- Frank N.Y., Margaryan A., Huang Y. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma//Cancer Res. -2005. Vol. 65. — P.4320−4333.
- Duelli D., Lazebnik Y. Cell fusion: a hidden enemy?//Cancer Cell. 2003. -Vol. 3. — P.445−448.
- Aleman C., Annereau J.P., Liang X.J. et al. P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential//Cancer Res. 2003. — Vol. 63. — P.3084−3091.
- Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis//J. Clin. Pharmacol. 2005. — Vol.45(8). -P. 872−877.
- La Porta C.A. Drug resistance in melanoma: new perspectives//Curr. Med. Chem. 2007. — Vol. 14(4). — P. 387−391.
- Lee CH. Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR)//Curr. Med. Chem. Anticancer Agents. 2004. — Vol. 4(1). — P. 43−52.
- Limtrakul P. Curcumin as chemosensitizer//Adv. Exp. Med. Biol. 2007. -Vol. 595. — P. 269−300.
- Lane A.H., Donahoe P.K. New insights into Mullerian inhibiting substance and its mechanism of action//J. Endocrinol. 1998. — Vol. 158. — P. 1−6.
- Jost A. Problems of fetal endocrinology: the gonadal and hypophyseal hormones/ZRecent Prog. Horm. Res. 1953. — Vol. 8. — P. 379−418.
- Barbie T.U., Barbie D.A., MacLaughlin D.T. et al. Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving pi30 and pl07//Proc. Natl. Acad. Sci. USA. 2003. — Vol. 100, N 26. — P. 15 601−15 606.
- Fuller A.F., Budzik G.P., Krane I.M., Donahoe P.K. Mullerian inhibiting substance inhibition of a human endometrial carcinoma cell line xenografted in nude mice//Gynecol. Oncol. 1984. — Vol. 17. — P. 124−132.
- Ha T.U., Segev D.L., Barbie D. et al. Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism//J. Biol. Chem. -2000. Vol. 275. — P. 37 101−37 109.
- Segev D.L., Ha T.U., Tran T.T. et al. Mtillerian Inhibiting Substance Inhibits Breast Cancer Cell Growth through an NF/cB-mediated Pathway//! Biol. Chem. -2000. Vol. 275, N 37. — P. 28 371−28 379.
- Segev D.L., Hoshiya Y., Hoshiya M. et al. Mullerian-inhibiting substance regulates NF-кВ signaling in the prostate in vitro and in vivo//Proc. Natl. Acad. Sci. USA. 2002. — Vol. 99. — P. 239−244.
- Гукасова H.B., Северин C.E. Белок MIS структура, регуляция экспрессии и молекулярный механизм действия//Вопр. биол. мед. и фарм. химии. — 2005. — № 4. — С. 3−9.
- Гукасова Н.В., Северин С. Е. Биологические функции белка MIS, его противоопухолевая активность и перспективы клинического применения//Вопр. биол. мед. и фарм. химии. 2006. — № 1. — С. 3−9.
- Cate R.L., Donahoe Р.К., MacLaughlin D.T. Mullerian inhibiting substance//Peptide Growth Factors and Their Receptors II//Eds. Sporn M.B., Roberts A.B. Berlin: Springer- Verlag. — 1990. — P. 179−210.
- Cate R.L., Mattaliano R.J., Hession C. et al. Isolation of the bovine and human genes for Mullerian inhibiting substance and expression of the human gene in animal cells//Cell. 1986. — Vol. 45. — P. 685−698.
- Lorenzo H.K., Teixeira J., Pahlavan N. et al. New approaches for high-yield purification of Mullerian inhibiting substance improves its bioactivity//J. Chromatogr. 2002. — Vol. 766. — P. 89−98.
- Ragin R.C., Donahoe P.K., Kenneally M.K. et al. Human Mullerian inhibiting substance: enhanced purification imparts biochemical stability and restores antiproliferative effects//Protein. Expr. Purif.- 1992. -Vol. 3. P.236−245.
- Teixeira J., Maheswaran S., Donahoe P.K. Mullerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications/ZEndocr. Rev. 2001. — Vol. 22. — P.657−674.
- Massague J. TGF-B signal transduction//Annu. Rev. Biochem. 1998. — Vol. 67. — P.753−791.
- Wrana J.L. Regulation of Smad activity//Cell. 2000. — Vol.100.- P. 189−192.
- Massague J., Wotton D. Transcriptional control by the TGF-B/Smad signaling system // EMBO J. 2000. — Vol. 19. — P. 1745−1754.
- Clemente N. Di, Josso N., Gouedard L., Belville C. Components of the anti-Mullerian hormone signaling pathway in gonads // Mol. Cell. Endocrinol. 2003. -Vol. 211.-P. 9−14.
- Visser J.А. АМН signaling: from receptor to target gene//Mol. Cell. Endocrinol. 2003. — Vol. 211. — P.65−73.
- Teixeira J., He W.W., Shah P.C. et al. Developmental expression of a candidate Miillerian inhibiting substance type II receptor//Endocrinology. 1996. -Vol. 137.-P. 160−165.
- Segev D.L., Hoshiya Y., Stephen A.E. et al. Miillerian Inhibiting Substance Regulates NF-/cB Signaling and Growth of Mammary Epithelial Cells in Vivo//J. Biol. Chem. 2001. — Vol. 276, N 29. — P. 26 799−26 806.
- Hoshiya Y., Gupta V., Segev D. L. et al. Mullerian Inhibiting Substance induces NFkB signaling in breast and prostate cancer cells//Mol. Cell. Endocrinol. -2003.-Vol. 211.-P. 43−49.
- Parry R. L., Chin T. W., Epstein J. et al. Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo//Cancer Res. 1992. — Vol. 52. — P. 1182−1186.
- Chin Т., Parry R. L., Donahoe P. K. Human Mullerian inhibiting substance inhibits tumor growth in vitro and in vivo//Cancer Res. 1991. — Vol. 51. -P.2101−2106.
- Stephen A. E., Pearsall L. A., Christian B. P. et al. Highly Purified Mullerian Inhibiting Substance Inhibits Human Ovarian Cancer in Vivo//Clinical Cancer Res. 2002. — Vol. 8. — P. 2640−2646.
- Stephen A.E., Masiakos P.T., Segev D.L. et al. Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo//Proc. Natl. Acad. Sci. USA. 2001. — Vol. 98. — P. 3214−3219.
- Fuller A. F., Krane I. M., Budzik G. P., Donahoe P. K. Miillerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay//Gynecol. Oncol. 1985. — Vol. 22. — P. 135−148.
- Hoshiya Y., Gupta V., Kawakubo H. et al. Mullerian Inhibiting Substance Promotes Interferon 7-induced Gene Expression and Apoptosis in Breast Cancer Cells//J. Biol. Chem. 2003. — Vol. 278, N 51. — P. 51 703−51 712.
- Mossman Т. Rapid colorimetric assay for cellular growth and cytotoxicity assays//J. Immunol. Meth. 1983. — Vol. 65. — P. 55−63.
- Towbin H., Staehelin Т., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications//Proc Natl Acad Sci USA. 1979. — Vol. 76. — P. 4350−4354.
- Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970. — Vol. 227. — P. 680−685.
- Родина A.B., Москалева Е. Ю., Беляев Д. Л. и др. Получение функционально активных дендритных клеток человека с использованием препарата лейкинферон в качестве индуктора созревания//Аллергия, астма и клиническая иммунология. 2003. — № 9 — 19−27.
- Goodell M.A., Brose К., Paradis G. et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo//J. Exp. Med. -1996.- V.183. P.1797−1806.
- Monzani E., Facchetti F., Galmozzi E. et al. Melanoma contains CD 133 and ABCG2 positive cells with enhanced tumourigenic potential//Eur. J. Cancer. -2007.-Vol. 43.-P. 935−946.
- Robey R.W., Steadman K., Polgar O., Morisaki K., Blayney M., Mistry P., Bates S.E. Pheophorbide a is a specific probe for ABCG2 function and inhibition/ZCancer Res. 2004. — Vol. 64. — P. 1242−1246.
- Kruger J.A., Kaplan C.D., Yunping Luo, He Zhou, Markowitz D., Xiang R. and Reisfeld R.A. Characterization of stem cell-like cancer cells in immune-competent mice//Blood. 2006. — Vol. 108. — P. 3906−3912.
- Wang S., Diller K.R., Aggarwal S.J. Kinetics Study of Endogenous Heat Shock Protein 70 Expression//Journal of Biomechanical Engineering. 2003. -Vol. 125.-P. 794−797.
- Welch W.J., Suhan J.P. Cellular and biochemical events in mammalian cells during and after recovery from phisiological stress//J. Cell. Biol. 1986. — Vol. 103.-P. 2035−2052.
- Blom D.J., De Waard-Siebinga I., Apte R.S. et al. Effect of hyperthermia on expression of histocompatibility antigens and heat-shock protein molecules on three human ocular melanoma cell lines//Melanoma Res. — 1997. Vol. 7(2) — P. 103−109.
- Dressel R., Johnson J.P., Gunther E. Heterogeneous patterns of constitutive and heat shock induced expression of HLA-linked HSP70−1 and HSP70−2 heat shock genes in human melanoma cell lines//Melanoma Res. 1998. — Vol. 8(6) -P.482−92.
- Ahmad S., Ahuja R., Venner T.J., Gupta R.S. Identification of a protein altered in mutants resistant to microtubule inhibitors as a member of the major heat shock protein (hsp70) family//Mol. Cell Biol. 1990. — Vol. 10(10). — P. 5160−5165.
- Abe Т., Konishi Т., Hirano T. et al. Possible correlation between DNA damage induced by hydrogen peroxide and translocation of heat shock 70 protein into the nucleus/ZBiochem. Biophys. Res. Commun. 1995. — Vol. 206. — P.548−555.
- Ciocca D.R., Fuqua S.A.W., Lock-Lim S. et al. Response of human breast cancer cells to heat shock and chemotherapeutic drugs // Cancer Res. 1992. -Vol. 52.-P. 3648−3654.
- Mosser D.D., Caron A.W., Bourget L. et al. Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis // Mol Cell Biol. -1997. Vol. 17. -P. 5317−5327
- Valavanis C., Y. Hu, Y. Yang et al. Model cell lines for the study of apoptosis in vitro//Methods in cell biology. 2001. — Vol. 66. — P. 417−436.
- Eisen M., Leibson P.J. The Fas pathway in apoptosisZ/Advances in Pharmacol. 1997. Vol. 41. — P. 107−132.
- Schadendorf D, Makki A, Stahr C, van Dyck A, Wanner R, Scheffer GL, Flens MJ, Scheper R, Henz BM. Membrane transport proteins associated with drug resistance expressed in human melanoma.//Am. J. Pathol. 1995. — Vol. 147(6).-P. 1545−1552.
- Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation//Curr. Cancer Drug Targets. 2003. — Vol. 3(1). — P. 1−19.